Kenneth T. Mills sold $886k of RGNX
President and CEO at REGENXBIO Inc.. 45,000 shares at an average of $19.69, traded Dec 19, 2023, filed Dec 21, 2023.
Score components
- +25RoleCEO
- +23Trade size$886k at market
- +5Share of holdings soldSold 11% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-23-008519, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 19, 2023 | MOption exercise Common Stock10b5-1 | +43,500 | $3.76 | $164k | 398,789 | Dec 21, 2023 |
| Dec 19, 2023 | MOption exercise Common Stock10b5-1 | +1,500 | $0.85 | $1,275 | 400,289 | Dec 21, 2023 |
| Dec 19, 2023 | SOpen-market sale Common Stock10b5-1 | -45,000 | $19.69 | $886k | 355,289 | Dec 21, 2023 |
| Dec 19, 2023 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -43,500 | $0.00 | $0 | 186,354 | Dec 21, 2023 |
| Dec 19, 2023 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 36,316 | Dec 21, 2023 |
Related signals
Other insiders at REGENXBIO Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 57Moderate | RGNXbuy REGENXBIO Inc. | Gregory Austin Ciongoli director | $949k 102,603 shares | +665% | |
| 0Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $29k 2,161 shares | -1% | |
| 6Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $689k 56,333 shares | -24% | |
| 6Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $169k 15,309 shares | -6% | |
| 2Weak | REGENXBIO Inc. | Steve Pakola Chief Medical Officer | $53k 5,124 shares | -2% | |
| 18Weak | REGENXBIO Inc. | Curran Simpson Chief Executive Officer | $263k 20,811 shares | -9% | |
| 13Weak | REGENXBIO Inc. | Curran Simpson Chief Executive Officer | $76k 7,624 shares | -3% | |
| 13Weak | REGENXBIO Inc. | Curran Simpson Chief Executive Officer | $77k 7,734 shares | -3% | |
| 0Weak | REGENXBIO Inc. | Kenneth T. Mills President and CEO | $163k 20,602 shares | -4% | |
| 13Weak | REGENXBIO Inc. | Kenneth T. Mills President and CEO | $328k 15,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.